Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Methoxsalen +ECP Clear all

Conditions: Acute Graft-versus-Host Disease
Interventions: Methoxsalen+ECP, Methylprednisolone, Ecp; Drug · Procedure
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more

Conditions: Bronchiolitis Obliterans Syndrome (BOS)
Interventions: Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.; Combination Product · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions: Extracorporeal Photopheresis (ECP), Methoxsalen; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: SoluMedrol, Extracorporeal Photopheresis; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Immune-related Colitis
Interventions: Methoxsalen, Infliximab, Vedolizumab; Drug
Lead sponsor: Therakos LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Steroid Refractory Acute Graft Versus Host Disease
Interventions: Methoxsalen, Extracorporeal Photopheresis (ECP); Drug · Procedure
Lead sponsor: Therakos, Inc., a Mallinckrodt Company; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more

Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: Methoxsalen +ECP, Extracorporeal Photopheresis; Drug · Procedure
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 4
States / cities: Bethesda, Maryland • Chevy Chase, Maryland • Morristown, New Jersey + 1 more

Conditions: Graft Versus Host Disease
Interventions: stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Graft Versus Host Disease, Cancer, Stem Cell Transplantation
Interventions: Extracorporeal Photopheresis; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sezary Syndrome
Interventions: Extracorporeal photopheresis (ECP), Methoxsalen Injection; Device · Drug
Lead sponsor: Oleg E. Akilov, MD, PhD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions: extracorporeal photopheresis; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions: Methoxsalen+ECP; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 7
States / cities: Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Hematologic Malignancies
Interventions: extracorporeal photopheresis, Pentostatin, Total Body Irradiation; Procedure · Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: New Haven, Connecticut • Boston, Massachusetts • San Antonio, Texas

Conditions: Chronic Graft Versus Host Disease
Interventions: ECP Methoxsalen, Standard of Care; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more

Search by objective public record fields.

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Photopheresis in Early-stage Mycosis Fungoides

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Extracorporeal Photopheresis for Acute Graft Versus Host Disease

Extracorporeal Photopheresis in Sezary Syndrome

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)